At the news
? NEUTRALIMPACT 4/10 6-K filed Aug 10, 2026 at 16:03 ET
Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is expected to enter the clinic in 2027. The company reported cash of $6.1M as of June 30, 2026, with a runway to mid-2027. The filing is a routine business update with no new material financial data or clinical results, but the cash runway and pre-revenue status are notable risks for a $2M market cap company.
- Cash of $6.1M as of June 30, 2026, with runway to mid-2027.
- Lead program IM1240 (cappedCD3x5T4xNKG2A) expected to enter the clinic in 2027.
- Pre-IND meeting completed; IND submission planned for 2027.
- Second program IM1305 (cappedCD3xTROP2xNKG2A) in preclinical development.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access